193 related articles for article (PubMed ID: 37678921)
1. Inhibition of TCA cycle improves the anti-PD-1 immunotherapy efficacy in melanoma cells via ATF3-mediated PD-L1 expression and glycolysis.
Liu N; Yan M; Tao Q; Wu J; Chen J; Chen X; Peng C
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37678921
[TBL] [Abstract][Full Text] [Related]
2. eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma.
Chen X; Wang K; Jiang S; Sun H; Che X; Zhang M; He J; Wen Y; Liao M; Li X; Zhou X; Song J; Ren X; Yi W; Yang J; Chen X; Yin M; Cheng Y
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35347072
[TBL] [Abstract][Full Text] [Related]
3. Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma.
Martins Nascentes Melo L; Herrera-Rios D; Hinze D; Löffek S; Oezel I; Turiello R; Klein J; Leonardelli S; Westedt IV; Al-Matary Y; Egea-Rodriguez S; Brenzel A; Bau M; Sucker A; Hadaschik E; Wirsdörfer F; Hanenberg H; Uhlenbrock N; Rauh D; Poźniak J; Rambow F; Marine JC; Effern M; Glodde N; Schadendorf D; Jablonska J; Hölzel M; Helfrich I
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37028818
[TBL] [Abstract][Full Text] [Related]
4. Mefloquine enhances the efficacy of anti-PD-1 immunotherapy via IFN-γ-STAT1-IRF1-LPCAT3-induced ferroptosis in tumors.
Tao Q; Liu N; Wu J; Chen J; Chen X; Peng C
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38471712
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of glycolysis enhances the efficacy of immunotherapy via PDK-mediated upregulation of PD-L1.
Zhang R; Mao G; Tang Y; Li C; Gao Y; Nie W; Song T; Liu S; Zhang P; Tao K; Li W
Cancer Immunol Immunother; 2024 Jun; 73(8):151. PubMed ID: 38832951
[TBL] [Abstract][Full Text] [Related]
6. Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.
Zhang X; Lao M; Xu J; Duan Y; Yang H; Li M; Ying H; He L; Sun K; Guo C; Chen W; Jiang H; Zhang X; Bai X; Liang T
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35260434
[TBL] [Abstract][Full Text] [Related]
7. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
8. Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors.
Zhang M; Wang L; Liu W; Wang T; De Sanctis F; Zhu L; Zhang G; Cheng J; Cao Q; Zhou J; Tagliabue A; Bronte V; Yan D; Wan X; Yu G
J Immunol Res; 2022; 2022():2253436. PubMed ID: 35785030
[TBL] [Abstract][Full Text] [Related]
9. Exercise sensitizes PD-1/PD-L1 immunotherapy as a hypoxia modulator in the tumor microenvironment of melanoma.
Yan H; Jiang A; Huang Y; Zhang J; Yang W; Zhang W; Liu T
Front Immunol; 2023; 14():1265914. PubMed ID: 37876940
[TBL] [Abstract][Full Text] [Related]
10. The traditional chinese medicine monomer Ailanthone improves the therapeutic efficacy of anti-PD-L1 in melanoma cells by targeting c-Jun.
Yu P; Wei H; Li K; Zhu S; Li J; Chen C; Zhang D; Li Y; Zhu L; Yi X; Liu N; Liu P; Zhao S; Chen X; Peng C
J Exp Clin Cancer Res; 2022 Dec; 41(1):346. PubMed ID: 36522774
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer.
Li X; Tang L; Chen Q; Cheng X; Liu Y; Wang C; Zhu C; Xu K; Gao F; Huang J; Wang R; Guan X
Chin Med J (Engl); 2022 Oct; 135(20):2436-2445. PubMed ID: 36583862
[TBL] [Abstract][Full Text] [Related]
12. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
13. Albendazole induces immunotherapy response by facilitating ubiquitin-mediated PD-L1 degradation.
Zhu L; Kuang X; Zhang G; Liang L; Liu D; Hu B; Xie Z; Li H; Liu H; Ye M; Chen X; Liu J
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35577504
[TBL] [Abstract][Full Text] [Related]
14. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
[TBL] [Abstract][Full Text] [Related]
15. Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma.
Que Y; Zhang XL; Liu ZX; Zhao JJ; Pan QZ; Wen XZ; Xiao W; Xu BS; Hong DC; Guo TH; Shen LJ; Fan WJ; Chen HY; Weng DS; Xu HR; Zhou PH; Zhang YZ; Niu XH; Zhang X
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637599
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of xCT suppresses the efficacy of anti-PD-1/L1 melanoma treatment through exosomal PD-L1-induced macrophage M2 polarization.
Liu N; Zhang J; Yin M; Liu H; Zhang X; Li J; Yan B; Guo Y; Zhou J; Tao J; Hu S; Chen X; Peng C
Mol Ther; 2021 Jul; 29(7):2321-2334. PubMed ID: 33744468
[TBL] [Abstract][Full Text] [Related]
17. Albendazole induces an anti-tumor effect and potentiates PD-L1 blockade immunotherapy.
Zhang W; He Z; Liang F; Gong J; Tan L; Yang J; Song S; Xie L; Lu Y
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16763-16778. PubMed ID: 37730912
[TBL] [Abstract][Full Text] [Related]
18. WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape.
Lu C; Liu Z; Klement JD; Yang D; Merting AD; Poschel D; Albers T; Waller JL; Shi H; Liu K
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326167
[TBL] [Abstract][Full Text] [Related]
19. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA.
Wu R; Wang C; Li Z; Xiao J; Li C; Wang X; Kong P; Cao J; Huang F; Li Z; Huang Y; Chen Y; Li X; Yang D; Zhang H; Mai J; Feng G; Deng R; Zhu X
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158915
[TBL] [Abstract][Full Text] [Related]
20. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
